ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Health Technology

Celltrion

  • 245,500.00 KRW
  • -5,500.00
  • -2.19%
  • South Korea
    Apr 25, 2018
  • Ticker
    KRX(068270)
  • Prev. close
    251,000
  • Market cap (KRW)
    31,402.20B
  • Market cap (USD)
    29,059.96M
  • Shares
    125.10M

Company Background

Celltrion is a South Korean pharmaceutical venture that develops "biosimilars" -- generic equivalents of biopharmaceuticals -- using microorganisms and animal cells. Remsima, a biosimilar treatment for rheumatoid arthritis, has been approved for sale in South Korea, Japan, Europe, Australia and Latin America.

Founded in 2002, Celltrion started out as a contract manufacturer for Western drug companies. It moved into biosimilars in 2008. The company's plants in South Korea can produce 200,000 liters of protein drugs per year.

In addition to well-known treatments Remsima and breast cancer drug Herzuma, the company develops and markets one to two new products a year. Celltrion plans to focus on developed markets, including Japan, the U.S. and Europe, where demand for biosimilars is growing rapidly.

Because Celltrion is a research and development-oriented company, its operating profit margin has remained high. It is one of the top companies on the Kosdaq market for startups in terms of market capitalization.

Business Summary

Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. It operates through the Biopharmaceuticals, Chemical Drugs and Others businesses. Its products include remsima and biosimilars. The company was founded on February 27, 1991 and is headquartered in Incheon, South Korea.

Financial Highlights

Dec 2017 KRWUSD
Revenue949,079.96M839.51M
Gross Profit677,802.43M599.55M
Operating income521,943.70M461.68M
Income before tax505,748.26M447.36M
Net income399,360.60M353.25M
EBITDA625,484.56M553.27M
Diluted EPS3,1872.81
Dividends Per Share----
Total Assets3,552.96B3,318.81M
Total liabilities977,407.18M912.99M
Total equity2,424.57B2,264.79M
Operating cash flow502,053.36M444.09M
Currency in KRWCurrency in USD

Historical Data

 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 226,207.86M 471,045.51M 603,412.76M 670,580.96M 949,079.96M
Gross Profit 148,546.04M 333,937.37M 361,042.87M 388,407.95M 677,802.43M
Operating income 99,376.25M 201,417.00M 258,922.92M 249,614.31M 521,943.70M
Income before tax 115,273.17M 149,377.60M 162,901.39M 228,752.75M 505,748.26M
Net income 102,454.82M 112,676.33M 154,089.61M 177,994.50M 399,360.60M
EBITDA 146,858.85M 277,695.81M 341,097.00M 338,289.64M 625,484.56M
Diluted EPS 896.15 959.08 1,271.70 1,425.49 3,187
Dividends Per Share 0 0 0 0 --
Total Assets 2,052.94B 2,394.26B 2,825.98B 3,117.56B 3,552.96B
Total liabilities 965,329.83M 1,045.80B 1,015.16B 914,607.61M 977,407.18M
Total equity 1,087.13B 1,247.39B 1,694.23B 2,053.63B 2,424.57B
Operating cash flow 108,724.75M 111,000.58M 45,199.75M 230,062.47M 502,053.36M
 Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017
Revenue 206.62M 447.48M 533.14M 577.99M 839.51M
Gross Profit 135.68M 317.23M 318.99M 334.77M 599.55M
Operating income 90.77M 191.34M 228.77M 215.14M 461.68M
Income before tax 105.29M 141.90M 143.93M 197.16M 447.36M
Net income 93.58M 107.03M 136.14M 153.41M 353.25M
EBITDA 134.14M 263.80M 301.37M 291.58M 553.27M
Diluted EPS 0.81 0.91 1.12 1.22 2.81
Dividends Per Share 0 0 0 0 --
Total Assets 1,945.27M 2,178.28M 2,410.12M 2,581.19M 3,318.81M
Total liabilities 914.70M 951.46M 865.77M 757.25M 912.99M
Total equity 1,030.11M 1,134.87M 1,444.91M 1,700.31M 2,264.79M
Operating cash flow 99.31M 105.44M 39.93M 198.29M 444.09M

Valuation Measures

Dec 2017
PER68.96
ROA11.97%
ROE17.83%
Operating margin54.99%
Profit margin42.07%

Key executives

  • Co-Chief Executive Officer & Director: Hyung-Ki Kim
  • Co-Chief Executive Officer & Director: Wu-Sung Ki
  • Head-Legal & Compliance Support: Sung-Han Lee
  • Vice President: Shin-Jae Jang
  • Vice President: Sang-Joon Lee

Shareholders

  • SEO JUNG-JIN (22.2%)
  • Temasek Holdings Pte Ltd. (Investment Management) (12.4%)
  • Schroder Investment Management Ltd. (1.6%)
  • BlackRock Fund Advisors (1.5%)
  • The Vanguard Group, Inc. (1.5%)
  • Celltrion Inc. Employee Stock Ownership ASSN. (0.8%)
  • Norges Bank Investment Management (0.8%)
  • OppenheimerFunds, Inc. (0.7%)
  • Samsung Asset Management Co., Ltd. (0.6%)
  • Celltrion, Inc. (0.4%)

Contact Details

Related Companies

  • Celltrion Inc. Employee Stock Ownership ASSN.
  • Celltrion Pharm Inc.

Competitors

  • Samsung BioLogics Co., Ltd.
  • EPIRUS Biopharmaceuticals, Inc.
  • Biocon Limited
  • Reyon Pharmaceutical Co., Ltd.
  • Oncobiologics, Inc.
  • Porton Pharma Solutions Ltd. Class A
Last Updated on 25 Apr, 2018

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media